Bayer Finds Partial Pharma Partner In Aventis Blood Products Joint Venture
Executive Summary
Bayer/Aventis Behring's blood products joint venture would partly accomplish Bayer's goal of finding a strategic partner for its pharmaceutical business
You may also be interested in...
Aventis/Bayer end joint venture
Aventis is "proactively exploring alternative options for the future of Aventis Behring" after ending joint venture negotiations with Bayer. "Both companies reviewed various possible forms of cooperation. A final agreement on the terms of the transaction could not be reached." Aventis and Bayer signed a letter of intent to combine their biologics business in February 2002 (1"The Pink Sheet" Feb. 25, 2002, p. 17). During the JP Morgan H&Q conference, Aventis said it viewed the biologics business as a non-core operation and hoped to form a JV or divest it in 2003...
Aventis/Bayer end joint venture
Aventis is "proactively exploring alternative options for the future of Aventis Behring" after ending joint venture negotiations with Bayer. "Both companies reviewed various possible forms of cooperation. A final agreement on the terms of the transaction could not be reached." Aventis and Bayer signed a letter of intent to combine their biologics business in February 2002 (1"The Pink Sheet" Feb. 25, 2002, p. 17). During the JP Morgan H&Q conference, Aventis said it viewed the biologics business as a non-core operation and hoped to form a JV or divest it in 2003...
Bayer Sheds R&D Projects Ahead Of Joint Venture, Is Flexible On Control
Bayer is reducing the size of its R&D pipeline through product eliminations and outlicensing opportunities to maximize its influence over a future pharmaceutical partnership, Management Board Chairman Werner Wenning announced Nov. 12